To improve the emission efficiency, the driving voltage and the lifetime of an organic light-emitting device using a delayed fluorescent material. A host material for a delayed fluorescent material, containing a compound represented by the following general formula: R.sup.1 to R.sup.5 each are a substituent not containing a cyano group, n1 to n5 each are 0 to 4, Ar is a monocyclic arylene group or a monocyclic heteroarylene group.

##STR00001##

An amine-containing compound represented by Formula 1, a light-emitting device including the amine-containing compound, and an electronic apparatus including the light-emitting device are provided:

##STR00001##

An amine-containing compound represented by Formula 1, a light-emitting device including the amine-containing compound, and an electronic apparatus including the light-emitting device are provided:

##STR00001##

Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.

Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.

The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are substituted 3-phenylpropylamine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.

The present invention relates to compounds of formula I: in which A.sup.1-A.sup.7 and R.sup.1 to R.sup.5 are defined herein, for use in the treatment of a condition or disease which is alleviated by the activation of retinoic acid receptors (RAR). The invention also relates to pharmaceutical compounds comprising such compounds, and related methods of treatment. In an aspect, the invention relates to a method of screening compounds for therapeutic potential in the treatment of a condition or disease which is alleviated by the activation of retinoic acid receptors (RAR). Aspects of the invention relate to novel compounds of formula I in which at least one of A.sup.1 to A.sup.3 is N or at least one of A.sup.4 is CR.sup.12 or A.sup.5 is CR.sup.13 in which R.sup.12/R.sup.13 is halogen.

The present invention relates to compounds of formula I: in which A.sup.1-A.sup.7 and R.sup.1 to R.sup.5 are defined herein, for use in the treatment of a condition or disease which is alleviated by the activation of retinoic acid receptors (RAR). The invention also relates to pharmaceutical compounds comprising such compounds, and related methods of treatment. In an aspect, the invention relates to a method of screening compounds for therapeutic potential in the treatment of a condition or disease which is alleviated by the activation of retinoic acid receptors (RAR). Aspects of the invention relate to novel compounds of formula I in which at least one of A.sup.1 to A.sup.3 is N or at least one of A.sup.4 is CR.sup.12 or A.sup.5 is CR.sup.13 in which R.sup.12/R.sup.13 is halogen.

The disclosure provides a compound shown in formula (I) and a prodrug thereof, which have a good MDM2 and/or MDMX inhibiting effect and may be used for treating MDM2 and/or MDMX-mediated symptoms and/or diseases such as neoplastic diseases and/or idiopathic pulmonary fibrosis and preparing drugs for such symptoms or diseases. In particular, a compound containing a phosphoric acid (phosphate) structure has higher solubility. As the prodrug, the compound can release an MDM2 and/or MDMX double-target inhibitor compound with high activity in an animal body, which solves the problem that such double-target inhibitors are hardly prepared into drugs.

The disclosure provides a compound shown in formula (I) and a prodrug thereof, which have a good MDM2 and/or MDMX inhibiting effect and may be used for treating MDM2 and/or MDMX-mediated symptoms and/or diseases such as neoplastic diseases and/or idiopathic pulmonary fibrosis and preparing drugs for such symptoms or diseases. In particular, a compound containing a phosphoric acid (phosphate) structure has higher solubility. As the prodrug, the compound can release an MDM2 and/or MDMX double-target inhibitor compound with high activity in an animal body, which solves the problem that such double-target inhibitors are hardly prepared into drugs.